Resolution at the extraordinary general meeting in Medivir on 11 March 2021
News provided by
Share this article
Resolution on a directed issue of shares
The extraordinary general meeting in Medivir Aktiebolag (publ) on 11 March 2021 resolved, in accordance with the board of directors' proposal, to raise approximately SEK 27,828,000 by a directed issue of not more than 3,600,000 new class B shares. The right to subscribe for the new class B shares in the directed issue is, with deviation from the shareholders' pre-emption rights, granted to LINC AB. The subscription price per share shall be SEK 7.73, corresponding to the closing price of Medivir's shares on 5 February 2021. The purpose of the issue, and the reason for the deviation from the shareholders' pre-emption rights, is to strengthen the company's institutional shareholder base and the proceeds will be used to accelerate the company's existing business plan, mainly focusing on the development of MIV-818.